Genomic testing and management of low-/intermediate-risk prostate cancer

A new paper has provided us with data on the ability of genomic testing to predict adverse pathology in a man undergoing a multiparametric MRI (mpMRI) and subsequent biopsy for risk of prostate cancer. … READ MORE …

Is the Decipher test really as useful as it’s manufacturer seems to claim?

A newly published article in the journal PLoS One questions whether the Decipher® test (a 22-gene expression assay test) has actual clinical utility in helping physicians to make good decisions about the follow-up treatment of men with prostate cancer after an initial radical prostatectomy. … READ MORE …

Gen-Probe submits application to market Progensa PCA3 assay

According to a corporate media release, issued yesterday, Gen-Probe has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) seeking approval to market the company’s version of the PCA3 test, known as Progensa®. … READ MORE …